Back to search
FDAFDA · Food and drugs·Recall number Z-2909-2020

Alaris System PC Unit Model 8015

Published September 16, 2020 · Recall initiated: August 4, 2020

Summary

FDA records medical device Class I recall Z-2909-2020, published September 16, 2020 and initiated August 4, 2020. Recalling firm: CareFusion 303, Inc.; Status: Ongoing; Reported quantity: 313740; Lot: All serial numbers manufactured from April 07, 2017 to Present. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

The pump module keypad may exhibit keys that are unresponsive or stuck as a result of fluid ingress potentially resulting in a delay to the start of infusion, interruption of infusion, or inability to titrate medication. For high-risk patient populations who are receiving life-sustaining infusions, delays in an infusion or interruption can cause serious injury or death.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
CareFusion 303, Inc.
Distributor
U.S.:LA, FL, KY, MI, AL, GA, CA, TN, NC, TX, MA, OH, CO, WI, IL, KS, MO, UT, AK, MD, NY, NV, VA, NE, IN, PA, VT, DC, SC, CT, AR, NJ, MT, ND ,HI , NH, WA, DE, ME, OR, MN, AZ, MS, IA, NM, WY, ID, OK, SD, WV, MP, GU O.U.S.: CA, AE, AU, BE, CA, CH, IL, IN, KW, N/A, NL, NZ, PH, QA, SA, SG, TW, US, ZA
Lot
All serial numbers manufactured from April 07, 2017 to Present.
Risk classification
Class I
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Alaris System PC Unit Model 8015 recalled?

Yes. FDA published recall Z-2909-2020 on September 16, 2020. Reported hazard: The pump module keypad may exhibit keys that are unresponsive or stuck as a result of fluid ingress potentially resulting in a delay to the start of infusion, interruption of infusion, or inability to titrate medication. For high-risk patient populations who are receiving life-sustaining infusions, delays in an infusion or interruption can cause serious injury or death.

What should I do if I have this product?

Voluntary: Firm initiated · Letter